Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

[1]  A. Goldstone,et al.  The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial , 2002, British journal of haematology.

[2]  N. Gorin.  Autologous stem cell transplantation for adult acute leukemia , 2002, Current opinion in oncology.

[3]  C. Ries,et al.  Autologous stem cell transplantation for advanced acute myeloid leukemia , 2002, Bone Marrow Transplantation.

[4]  R. Stone,et al.  The challenge of acute myeloid leukemia in older patients , 2002, Current opinion in oncology.

[5]  A. Wåhlin,et al.  Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia , 2001, British journal of haematology.

[6]  F. Ferrara,et al.  Acute myeloid leukemia in the elderly: biology and therapeutic strategies. , 2001, Critical reviews in oncology/hematology.

[7]  C. Schiffer.  Acute myeloid leukemia in adults: where do we go from here? , 2001, Cancer Chemotherapy and Pharmacology.

[8]  C. Sawyers,et al.  Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission , 2001, Leukemia.

[9]  William H. Bensinger,et al.  Blood or marrow? , 2000, The Lancet.

[10]  F. Frassoni.  Randomised studies in acute myeloid leukaemia: the double truth , 2000, Bone Marrow Transplantation.

[11]  G. Schiller,et al.  Autologous bone marrow transplantation in acute leukemia. , 1999, Hematology/oncology clinics of North America.

[12]  F. Appelbaum,et al.  Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. , 1998, The New England journal of medicine.

[13]  Keith Wheatley,et al.  Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial , 1998, The Lancet.

[14]  R. Larson,et al.  Long‐term follow‐up of cancer and leukemia group B studies in acute myeloid leukemia , 1997, Cancer.

[15]  P. Hurteloup,et al.  Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). , 1997, Blood.

[16]  M. Labopin,et al.  Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). , 1997, Leukemia.

[17]  M. Labopin,et al.  Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years , 1997, Leukemia.

[18]  J. Niland,et al.  In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Singhal,et al.  Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. , 1995, Bone marrow transplantation.

[20]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[21]  Stephen L. George,et al.  Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia , 1995 .

[22]  F. Mandelli,et al.  Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. , 1995, The New England journal of medicine.

[23]  F. Mandelli,et al.  Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. , 1995, Blood.

[24]  M. Labopin,et al.  One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. , 1994, Blood.

[25]  R. Mayer,et al.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. , 1994, The New England journal of medicine.

[26]  S. Nimer,et al.  Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia , 1992 .

[27]  B. Clarkson,et al.  Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. , 1992, The New England journal of medicine.

[28]  D. Reece,et al.  High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. , 1991, Blood.

[29]  R. Gale,et al.  Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. , 1990, Cancer genetics and cytogenetics.

[30]  W. Hiddemann,et al.  Treatment strategies in acute myeloid leukemia (AML) , 1990, Blut.

[31]  P. Sonneveld,et al.  Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  B. Dörken,et al.  Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. , 1989, Blood.

[33]  J. Fay,et al.  High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  R. Priore,et al.  Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Crowley,et al.  Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. , 1984, Annals of internal medicine.

[36]  C. Begg,et al.  A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. , 1984, Blood.

[37]  S W Lagakos,et al.  Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. , 1982, Biometrics.

[38]  H. Gralnick,et al.  Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative Group , 1976, British journal of haematology.

[39]  C. Spurr,et al.  Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. , 1968, Blood.

[40]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. , 2000, Blood.

[41]  M. Labopin,et al.  Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis , 2000, Bone Marrow Transplantation.

[42]  P. Allison.  Survival analysis using the SAS system : a practical guide , 1995 .

[43]  S. Nimer,et al.  Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.